Artigas Rocío A, Gonzalez Angel, Riquelme Erick, Carvajal Cristian A, Cattani Andreína, Martínez-Aguayo Alejandro, Kalergis Alexis M, Pérez-Acle Tomas, Fardella Carlos E
Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Lira 85, 5 degrees piso, 8330074 Santiago, Chile.
J Clin Endocrinol Metab. 2008 Aug;93(8):3097-105. doi: 10.1210/jc.2008-0048. Epub 2008 May 20.
Familial glucocorticoid deficiency (FGD) is an autosomal recessive disorder characterized by unresponsiveness to ACTH. In this study, two mutations of the ACTH receptor (MC2R) gene are reported in this FGD clinical case.
The objective of the study was to characterize a novel MC2R gene mutation in a compound heterozygous patient with FGD phenotype.
This was a clinical case description, biochemical, molecular, and bioinformatics analysis to describe a novel MC2R gene mutation.
The subject of the study was a male diagnosed with primary adrenal insufficiency. The family history showed nonconsanguineous healthy parents, three healthy siblings, and one brother affected with FGD.
The mutant MC2R-Ala126Ser showed significantly lower activity when it was stimulated with ACTH-(1-24) than did cells transfected with wild-type MC2R.
The molecular studies demonstrated the presence of an adenine heterozygous insertion (InsA1347) in the MC2R gene (G217fs) in the patient. This insertion was due to a frame shift mutation in one allele and a premature stop codon codifying an aberrant receptor of 247 residues (27.2 kDa). We also found a novel heterozygous mutation alanine 126 by serine. Molecular dynamic simulations showed that serine 126 side chain fluctuates forming a noncanonical intrahelical hydrogen bond in the transmembrane helix 3 of the mutated receptor. This produces a structural rearrangement of the MC2R internal cavities that may affect the ligand recognition and signal transduction throughout the G protein.
We propose a molecular explanation for the reduced activity exhibited by the MC2R alanine 126 by serine mutant.
家族性糖皮质激素缺乏症(FGD)是一种常染色体隐性疾病,其特征为对促肾上腺皮质激素(ACTH)无反应。在本研究中,报道了该FGD临床病例中促肾上腺皮质激素受体(MC2R)基因的两种突变。
本研究的目的是鉴定一名具有FGD表型的复合杂合子患者中一种新的MC2R基因突变。
这是一项临床病例描述、生化、分子和生物信息学分析,以描述一种新的MC2R基因突变。
研究对象为一名被诊断为原发性肾上腺功能不全的男性。家族史显示父母非近亲结婚且健康,三个兄弟姐妹健康,一个兄弟患有FGD。
与转染野生型MC2R的细胞相比,突变型MC2R-Ala126Ser在用ACTH-(1-24)刺激时活性显著降低。
分子研究表明该患者的MC2R基因(G217fs)中存在腺嘌呤杂合插入(InsA1347)。这种插入是由于一个等位基因中的移码突变和一个过早的终止密码子,编码一个247个残基(27.2 kDa)的异常受体。我们还发现了一个新的杂合突变,即丙氨酸126突变为丝氨酸。分子动力学模拟显示,丝氨酸126侧链发生波动,在突变受体的跨膜螺旋3中形成一个非典型的螺旋内氢键。这导致MC2R内部腔室的结构重排,可能影响配体识别和通过G蛋白的信号转导。
我们对MC2R丙氨酸126突变为丝氨酸的突变体活性降低提出了分子解释。